| Patent Number |
Title Of Patent |
Date Issued |
| 7273861 |
Non-nucleoside reverse transcriptase inhibitors |
September 25, 2007 |
| Compounds represented by formula 1: ##STR00001## wherein R.sup.1 is H, halogen, (C.sub.1-4)alkyl, O(C.sub.1-4)alkyl, and haloalkyl; R.sup.2 is H or methyl; R.sup.3 is H or (C.sub.1-4)alkyl; R.sup.4 is H or (C.sub.1-4)alkyl; R.sup.5 is (C.sub.1-4)alkyl, (C.sub.1-4)alkyl(C.sub.3-7)cyc |
| 7105510 |
Non-nucleoside reverse transcriptase inhibitors |
September 12, 2006 |
| Compounds represented by formula I: ##STR00001## wherein R.sup.1 is H, halogen, (C.sub.1-4)alkyl, O(C.sub.1-4)alkyl, and haloalkyl; R.sup.2 is H or (C.sub.1-4)alkyl; R.sup.3 is H or (C.sub.1-4)alkyl; R.sup.4 is (C.sub.1-4)alkyl, (C.sub.1-4)alkyl(C.sub.3-7)cycloalkyl, or (C.sub.3-7)c |
| 6716836 |
Non-nucleoside reverse transcriptase inhibitors |
April 6, 2004 |
| A compound of formula I: ##STR1##wherein A is a connecting chain of (C.sub.1-3) alkyl; B is O or S; R.sup.1 is H, (C.sub.1-6) alkyl, halo, CF.sub.3, or OR.sup.1a wherein R.sup.1a is H or (C.sub.1-6)alkyl; R.sup.2 is H or Me; R.sup.3 is H or Me; R.sup.4 is H, (C.sub.1-4) alkyl, (C. |
| 6706706 |
Non-nucleoside reverse transcriptase inhibitors |
March 16, 2004 |
| Disclosed are compounds of formula I: ##STR1##wherein R.sup.2 is H, halogen, (C.sub.1-4)alkyl, O(C.sub.1-4)alkyl, NH(C.sub.1-4 alkyl) or N(C.sub.1-4 alkyl).sub.2 ; R.sup.4 is H or CH.sub.3 ; R.sup.5 is H or CH.sub.3 ; R.sup.12 is H, halogen, (C.sub.1-4)alkyl, CF.sub.3, or NO.sub. |
| 6673791 |
Non-nucleoside reverse transcriptase inhibitors |
January 6, 2004 |
| Compounds represented by formula I: ##STR1##wherein R.sup.2 is H, halogen, NHNH.sub.2, (C.sub.1-4)alkyl, O(C.sub.1-6)alkyl, and haloalkyl; R.sup.4 is H or Me; R.sup.5 is H or (C.sub.1-4)alkyl; R.sup.11 is (C.sub.1-4)alkyl, (C.sub.1-4)alkyl(C.sub.3-7)cycloalkyl, or (C.sub.3-7)cycloalk |
| 6313095 |
Antiherpes tetrapeptide derivatives having a substituted aspartic acid side chain |
November 6, 2001 |
| Disclosed herein are tetrapeptide derivatives of the formula X--NH--CHR.sup.1 --C(W.sup.1)--NR.sup.2 --CH[CH.sub.2 C(O)--Y]--C(W.sup.2)--NH--CH[CR.sup.3 (R.sup.4)--COOH]--C(W.sup.3)--NH--CHR.sup.5 --Z wherein X is a terminal group, for example, alkanoyl or phenylalkanoyl radicals, R. |
| 6242439 |
Azetidinone derivatives for the treatment of HCMV infections |
June 5, 2001 |
| A compound of formula I ##STR1##wherein R.sup.1 is hydrogen, methyl, ethyl, methoxy or methylthio; R.sup.2 and R.sup.3 each independently is hydrogen or lower alkyl; R.sup.4 is hydrogen, lower alkyl, methoxy, ethoxy or benzyloxy; R.sup.5 is lower alkyl, lower cycloalkyl, (CH.sub.2).s |
| 6239125 |
Azetidinone derivatives for the treatment of HCMV infections |
May 29, 2001 |
| A compound of formula 1: ##STR1##wherein Y is S or O;R.sub.1 is C.sub.1-6 alkyl; (C.sub.0-6 alkyl)aryl; (C.sub.0-6 alkyl)Het; orR.sub.1 is an amino acid analog or dipeptide analog of the formula: ##STR2##wherein R.sub.2 is H, C.sub.1-10 alkyl; or an amide or ester group;A is C.sub.6-10 aryl, |
| 6211170 |
Azetidinone derivatives for the treatment of HCMV infections |
April 3, 2001 |
| A compound of formula I: ##STR1##wherein R.sub.1 is hydrogen, methyl, ethyl, methoxy or methylthio; R.sub.2 and R.sub.3 each independently is hydrogen or C.sub.1-3 alkyl; R.sub.4 is hydrogen, lower alkyl, methoxy, ethoxy, or benzyloxy; R.sub.5 is lower alkyl, lower cycloalkyl, (CH.su |
| 5846941 |
Isosteric antiherpes peptide derivatives II |
December 8, 1998 |
| Disclosed herein are peptidomimetic compounds of the formula A--B--D--CH.sub.2 CH{CH.sub.2 C(O)R.sup.1 }C(O)--NHCH{CR.sup.2 (R.sup.3)COOH}C(O)--E wherein A is a terminal group, for example an optionally substituted phenylalkanoyl, and B is a N-methyl amino acid residue; or A and B to |
| 5830864 |
Antiherpes peptide derivatives having a ureido n-terminus |
November 3, 1998 |
| Disclosed herein are peptide derivatives of the formulawherein A is a terminal group, for example, an alkylaminocarbonyl or a phenylalkylaminocarbonyl; B is an amino acid residue; R.sup.1 is alkyl, cycloalkyl or a disubsubstituted amino; R.sup.2 is hydrogen or alkyl and R.sup.3 is alkyl, |
| 5700780 |
Antiviral peptide derivatives having a 2-oxoalkyl amino acid side chain |
December 23, 1997 |
| Disclosed herein are peptide derivatives of the formula X[--NR.sup.1 --CH(R.sup.2)--C(W.sup.1)].sub.n --NH--CR.sup.3 (R.sup.4)--C(W.sup.2)--NR.sup.5 --CH[CH.sub.2 C(O)--Y]--C(W.sup.3)--NH--CR.sup.6 --[CR.sup.7 --(R.sup.8)--COOH]--C(W.sup.4)--NH--CR.sup.9 (R.sup.10)--Z wherein X is a |
| 5574015 |
Isosteric antiherpes peptide derivatives |
November 12, 1996 |
| Disclosed herein are peptide derivatives of the formula A-B-D-CH.sub.2 CH{CH.sub.2 C(O)R.sup.1 }C(O)-NHCH{CR.sup.2 (R.sup.3)COOH}C(O)-E wherein A is a terminal group, for example an optionally substituted phenylalkanoyl, and B is a N-methyl amino acid residue; or A and B together form a |
| 5552384 |
Antiherpes compositions and method of use |
September 3, 1996 |
| Disclosed herein is a combination of an antiviral nucleoside analog and a ribonucleotide reductase inhibiting peptide derivative. The combination is useful for combatting herpes infections. |
| 5502036 |
Antiherpes pentapeptide derivatives having a substituted aspartic acid side chain |
March 26, 1996 |
| Disclosed herein are pentapeptide derivatives of the formula X--NR.sup.1 --CH(R.sup.2)--C(W)--NH--CR.sup.3 (R.sup.4)--C(W.sup.2)--NR.sup.5 --CH[CH.sub.2 C(O)--Y]--C(W.sup.3)--NH--CR.sup.6 --[CR.sup.7 (R.sup.8)--COOH]--C(W.sup.4)--NH--CR.sup.9 (R.sup.10)--Z wherein X is a terminal gro |
| 5484771 |
Antiherpes peptide derivatives having a 1,4-dioxo-C, N-terminus |
January 16, 1996 |
| Described herein are peptide derivatives of the formula R.sup.1 NH--CO--Q--C(O)--NR.sup.2 --CH[CH.sub.2 C(O)--Y]--C(O)--NH--CH[CR.sup.3 (R.sup.4)--COOH]--C(W)--NH--CHR.sup.5 --Z wherein R.sup.1 is an optionally substituted alkyl or optionally substituted phenylalkyl, R.sup.2 is hydro |
| 5476841 |
Inhibitors of herpes viral ribonucleotide reductase |
December 19, 1995 |
| Peptide derivatives are of the formula A--B--D--NHCH{CH.sub.2 C(O)R.sup.1 }C(O)--NHCH{CR.sup.2 (R.sup.3)--COOH}C(O)--E wherein A is a lower alkanoyl bearing two substituents, each substituent selected independently from phenyl or a monosubstituted phenyl wherein the monosubstituent is al |
| 5380727 |
Synergistic combination for treating herpes infections |
January 10, 1995 |
| Disclosed herein is a combination of an antiviral nucleoside analog and a ribonucleotide reductase inhibiting peptide derivative. The combination is useful for treating herpes infections. |
| 4841043 |
Stereoselective synthesis of 1-.beta.-alkyl carbapenem antibiotic intermediates |
June 20, 1989 |
| There is disclosed a process for producing carbapenam diazo intermediates of the formula ##STR1## wherein R.sup.1 is hydrogen or a hydroxy-protecting group,R.sup.2 is a lower alkyl having from 1-6 carbon atoms, andR.sup.3 represents a conventional carboxyl-protecting group.The processs c |
| 4788282 |
Deprotection of allylic esters and ethers |
November 29, 1988 |
| A process is disclosed for the deprotection of allylic esters and ethers. The process comprises reacting an allyl ester of a carboxylic acid or an allyl ether of a phenol with pyrrolidine or piperidine and a catalytic amount of an organic-soluble palladium complex having a coordinating |
